[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tobacco-use-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tobacco-use-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,46,90,124,153,179,201,229,252,278,310,339,382,403,430,455,478,498,521,545,569,599,621,643,666],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100474044","phase-2-5-ht2a-agonist-psilocybin-in-the-treatment-of-tobacco-use-disorder-100474044",false,"NCT05452772","5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","Inclusion Criteria:\n\n* 21 years old or older\n* Be a daily smoker (minimum of 5 cigarettes\u002Fday on a typical day and breath CO of 6 or greater at screening) with multiple unsuccessful previous quit attempts, and report a continued desire to quit smoking\n* Read, write, and speak English\n* Agree to abstain from smoking for the psilocybin\u002Fniacin session from 1 hour before psilocybin\u002Fniacin administration until at least 8 hours afterward\n* Agree to refrain from using any psychoactive drugs, including alcoholic beverages, within 24 hours of psilocybin\u002Fniacin administration\n* Be healthy as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis lab tests. See Exclusion Criteria below for specific ECG and specific blood test criteria\n\nExclusion Criteria:\n\n* The use of e-cigarettes or tobacco products other than machine-manufactured combustible cigarettes (e.g., cigarillos) on more than 5 of the previous 30 days\n* Women who are pregnant (positive pregnancy test) or nursing, or are not practicing an effective means of birth control\n* Positive urine drug screen for illicit drugs (excluding cannabis)\n* Positive urine breath test for alcohol. Participants with positive tests will be rescheduled\n* For blood samples, the following lab values will be exclusionary: transaminases greater than x2 the upper limit of normal lab reference range, hemoglobin less than 11 g\u002Fd, and creatinine clearance \\\u003C 40 ml\u002Fmin using the Cockroft-Gault equation.\n* For ECG screening: The ECG will be read by a cardiologist. Corrected heart rate (QTc) greater than 450 msec will be excluded.\n* Patients who have baseline vital signs that exceed the following measurements will be excluded from participation: Systolic blood pressure (SBP) \\> 139 mmHG, diastolic blood pressure (DBP)\\> 89 mmHG, and heart rate of \\\u003C=95 beats per minute (BPM). The investigators will perform serial heart rate monitoring with 3 total attempts. That is, heart rate must be \\\u003C=95 bpm on one of these attempts to be included in the study.\n* Currently taking on a regular basis (e.g., daily) antidepressants of any drug class, antipsychotics, or monoamine oxidase inhibitors (MAOIs), or serotonin-acting dietary supplements (e.g., 5-hydroxy- tryptophan, St. John's wort). Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or uridine diphosphate glucuronosyltransferase 1-9 (UGT1A9) inhibitors or uridine diphosphate glucuronosyltransferase 1-10 (UGT1A10) inhibitors such as phenytoin, regorafenib, eltrombopag. For individuals who have intermittent or \"as needed\" use of such medications, psilocybin sessions will not be conducted until at least 5 half-lives of the agent have elapsed after the last dose\n* Current use of medications for smoking cessation (i.e., varenicline, nicotine replacement products, bupropion)\n* Current neurological illnesses including, but not limited to, seizure disorders, frequent migraines or on prophylaxis, multiple sclerosis, movement disorders, history of significant head trauma (loss of consciousness \\> 24 hours), or central nervous system (CNS) tumor\n* Recent (within the past 12 months) or an extensive history of psychedelic use (\\>20 lifetime uses)\n* Current or past history of meeting Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), or Bipolar I or II Disorder. Current or past history within the last 5 years of meeting DSM-5 criteria for alcohol or drug use disorder (excluding caffeine and nicotine) or severe major depression\n* Recent (past year) history of suicidal behavior or attempt or high-level current suicidal ideation assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n* Have a first- or second-degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or bipolar I or II disorder\n* Currently meets DSM-5 criteria for Dissociative Disorder, Anorexia Nervosa, Bulimia Nervosa, Major Depression, or Post-traumatic Stress Disorder",true,"ALL","21 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Four sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University (NYU). The proposed study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in session 1 and either 30 mg or 40 mg in session 2); or 2) oral niacin (150 mg in session 1 and either 150 mg or 200 mg in session 2), with sessions 1 week apart.",[27],"Tobacco Use Disorder",[29,30,31,32],"Smoking Cessation","Smoking","Cigarettes","Cigarette Smoking","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":37},"2023-11-01",{"date":41,"type":21},"2027-05",{"name":43,"class":44},"Johns Hopkins University","OTHER",3,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100641150","launchpad-supporting-healthy-decisions-and-preventing-drug-use-after-high-school-100641150","NCT07655609","LaunchPad: Supporting Healthy Decisions and Preventing Drug Use After High School","Preventing Drug Use Onset and Progression Toward Addiction During a Critical Transition Period: Optimizing an Online Intervention for High School Seniors","Schools:\n\n* Public or private school in the U.S. enrolling 12th grade students\n* Agree to (1) provide us contact information for students and parents (or to send study information to students and parents themselves), (2) identify a school contact person (typically a school counselor) who will work with us to carry out the study (recruitment, pretest survey, intervention deployment, posttest survey), and (3) either provide school time to complete the intervention or integrate the intervention into a class (e.g., as an out-of-class assignment)\n\nStudents:\n\n* Enrolled as a 12th grade student at one of the participating schools\n* Have not completed a previous version of the intervention before\n* Between the ages of 15 and 21 years of age","15 Years",{"count":55,"type":21},5000,[57],"NA","LaunchPad is an online substance use prevention program for high school seniors. The program is designed to help seniors develop skills and make informed decisions as they transition from high school to young adulthood.\n\nThe purpose of this clinical trial is to learn whether individual LaunchPad lessons improve the specific attitudes, intentions, and skills they are designed to address. For example, researchers will examine whether the stress management lesson increases students' intentions to use healthy ways of managing stress.\n\nThe main question this study aims to answer is: Does each individual LaunchPad lesson improve the specific outcomes it was designed to address?\n\nResearchers will compare students who receive a particular lesson with students who do not receive that lesson to determine whether the lesson changes the intended outcome.\n\nParticipants will:\n\n* Complete a brief baseline survey\n* Complete two introductory online lessons\n* Complete one or more randomly assigned LaunchPad lessons\n* Complete a brief follow-up survey\n\nAll surveys and lessons will be completed online.",[60,61,27,62],"Substance-related Disorders","Alcohol-Related Disorders","Marijuana Use",[64,65,66,67,68,69,70,71,72,73,74,75,76,77,78],"Adolescence","Adolescent and Young Adult","Alcohol","Behavior","Decision Making","Development","Expectancy","High School Student","Intervention","Marijuana","Schools","Substance Use Prevention","Transition out of high school","Multi-phase Optimization Strategy","Normative Education","NOT_YET_RECRUITING","2026-06-22",{"date":82,"type":37},"2026-06-25",{"date":84,"type":21},"2026-09-01",{"date":86,"type":21},"2029-04-30",{"name":88,"class":89},"Prevention Strategies, LLC","INDUSTRY",{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":123},"100590357","phase-4-varenicline-for-smoking-reduction-in-veterans-not-ready-to-quit-100590357","NCT06966362","Varenicline for Smoking Reduction in Veterans Not Ready To Quit","Varenicline for Smoking Reduction in Veterans Unwilling to Quit","Inclusion Criteria:\n\n* Report smoking an average of 5 or more cigarettes daily for the previous 6 months\n* Not ready to set a quit date in the next 30 days but willing to cut down on their smoking\n* Able to read, write, and speak English\n* Be medically eligible to use study medications (NRT or varenicline)\n* If female, use an approved method of birth control while using study medication\n* Be at least 21 years old\n* Be a Veteran\n\nExclusion Criteria:\n\n* Unable to give informed, voluntary consent to participate\n* Current use of any pharmacotherapy for smoking cessation\n* Use of non-cigarette tobacco products as primary form of tobacco use\n* Incarceration",{"count":98,"type":21},400,[100],"PHASE4","In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.",[103,27,32,104],"Veterans","Tobacco Dependence",[106,107,103,108,109,110,111,112,113],"Varenicline","Tobacco use disorder","Quit attempts","Cigarette smoking","Motivation phase treatment","Nicotine replacement therapy","Smoking reduction","Smoking abstinence","2026-06-18",{"date":80,"type":37},{"date":117,"type":21},"2026-07-20",{"date":119,"type":21},"2030-06-28",{"name":121,"class":122},"VA Office of Research and Development","FED",4,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":16,"sex":17,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":45},"100568999","phase-4-e-cigarette-cessation-in-adults-who-co-use-cannabis-100568999","NCT06688539","E-cigarette Cessation in Adults Who Co-use Cannabis","A Prospective Trial of Varenicline and Incentives for E-cigarette Cessation in Adults Who Co-use Cannabis","VapeCAT","Inclusion Criteria:\n\n* Between the ages of 18 and 40 years old\n* Use e-cigarettes daily or near daily in the past month\n* Must submit a positive instant-read urine cotinine test at screening (≥ 200 ng\u002Fml)\n* Be interested in quitting use of e-cigarettes\n* Must be willing to take varenicline for the standard 12-week course of treatment\n* Self-reported use of cannabis on at least 10 out of the past 30 days or must submit a positive qualitative urinary cannabinoid test at screening (\\> 50 ng\u002Fml)\n\nExclusion Criteria:\n\n* Any serious or unstable medical\u002Fpsychiatric disorder (including severe substance use disorders, other than cannabis or tobacco use disorders) in the past three months that may interfere with study performance\n* Use of cigarettes on 10+ days in the past 30\n* Currently pregnant or breastfeeding\n* Current use of medications with smoking cessation efficacy\n* Use of any medications that would interfere with varenicline","18 Years","40 Years",{"count":135,"type":21},105,[100],"The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicline is not FDA approved for e-cigarette cessation, but is FDA approved for cigarette cessation. Investigators are also interested in how cannabis\u002Fmarijuana and tobacco interact during a tobacco quit attempt. All participants will receive e-cigarette cessation treatment for 12 weeks. To qualify, participants must be between the ages of 18-40 and use both e-cigarettes and cannabis. Participants do not need to be interested in quitting cannabis to qualify. This study is being conducted at three sites: the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and MUSC Lancaster in Lancaster, SC.",[139,27],"Nicotine Dependence",[141,142,143],"e-cigarettes","cannabis","treatment","2026-06-10",{"date":146,"type":37},"2026-06-12",{"date":148,"type":37},"2025-02-19",{"date":150,"type":21},"2027-06-01",{"name":152,"class":44},"Medical University of South Carolina",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":16,"sex":17,"minAge":132,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},"100534478","young-adult-tobacconicotine-and-cannabis-co-use-100534478","NCT06239350","Young Adult Tobacco\u002FNicotine and Cannabis Co-use","The Impact of Cannabis and Tobacco\u002FNicotine Product Co-use in Young Adults: Prospective Cessation Evaluation and Substitution","YouthCAT","Inclusion Criteria:\n\n* Between the ages of 18 and 25 years old\n* Must use at least one nicotine or tobacco product (nicotine vaping and\u002For cigarettes) on at least 20 out of the past 30 days for at least the past 3 months\n* Must express interest in nicotine cessation (all products)\n* Must submit a positive instant-read, oral fluid cotinine sample prior to enrollment\n* Must report use of cannabis on at least 10 out of the past 30 days\n* Must submit a positive instant-read cannabinoid test prior to enrollment\n* Must be able to provide informed consent\n\nExclusion Criteria:\n\n* Any significant or acutely unstable medical, psychiatric, or substance use problem that would contraindicate research, interfere with safety, compromise data integrity, or preclude consistent study participation\n* Pregnant (self-report) or trying to become pregnant\n* Self-reported use of medications with smoking cessation efficacy\n* Immediate interest in cannabis cessation or treatment","25 Years",{"count":163,"type":21},350,[57],"The goal of this project is to better understand the relationship between tobacco\u002Fnicotine and cannabis using behavioral economics during a tobacco\u002Fnicotine quit attempt. All participants will receive tobacco\u002Fnicotine cessation treatment (smoking and\u002For vaping treatment) for 12 weeks. To qualify, participants must be between the ages of 18-25 and use tobacco products (smoke cigarettes and\u002For vape nicotine) and use cannabis (in any form). Participants do not need to be interested in quitting cannabis\u002Fmarijuana to qualify. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed.",[27,139],[168,169,170,171],"tobacco","vaping","cessation","cannabis\u002Fmarijuana",{"date":146,"type":37},{"date":174,"type":37},"2024-05-13",{"date":176,"type":21},"2028-01-03",{"name":152,"class":44},1,{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":199,"locationsCount":178},"100636358","impact-of-novel-vs-usual-brand-menthol-cigarettes-on-abuse-liability-100636358","NCT07564648","Impact of Novel vs. Usual Brand Menthol Cigarettes on Abuse Liability","Inclusion Criteria:\n\n* Aged 21 years or older\n* Currently smoke cigarettes daily (≥ 5 cigarettes\u002Fday) for at least the past 6 months, and their usual brand is menthol cigarettes\n* Willing to provide informed consent\n* Willing to abstain from all nicotine, tobacco, and smoked cannabis products for approximately 12 hours prior to each study visit\n* Own and regularly use a functional smartphone compatible with study procedures (e.g., completing daily assessments)\n* Willing to complete two weeks of daily assessments involving use of their usual brand menthol cigarettes and the study product\n* Able to read, speak, and understand English\n\nExclusion Criteria:\n\n* Current diagnosis of any significant lung diseases (e.g., asthma, chronic obstructive pulmonary disease, cystic fibrosis)\n* History of a cardiac event or episode of cardiac distress (e.g., heart attack, hospitalization for chest pain) within the past 3 months\n* Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding\n* Self-reported use of any non-cigarette nicotine or tobacco product (e.g., e-cigarettes, cigars, oral nicotine products) or cannabis on more than 10 days in the past 30 days\n* Self-reported current participation in a smoking cessation program or intention to quit smoking in the next 3 months\n* Self-reported difficulty with blood draws",{"count":186,"type":21},48,[57],"This randomized, double-blind, crossover human laboratory study compares the abuse liability of cigarettes containing menthol and non-menthol cigarette variants, using the participant's usual brand menthol cigarette as a within-subject reference. Participants complete standardized laboratory smoking sessions, behavioral economic tasks, and a naturalistic observational period. The study examines differences in nicotine delivery, smoking behavior, and subjective effects across cigarette types in laboratory and real-world contexts.",[190,27],"Cigarette Addiction",[190,192],"Cigarette","2026-06-03",{"date":195,"type":37},"2026-06-05",{"date":80,"type":21},{"date":198,"type":21},"2029-09-30",{"name":200,"class":44},"Ohio State University Comprehensive Cancer Center",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100642885","phase-2-thcv-treatment-for-smokers-100642885","NCT07636356","THCV Treatment for Smokers","Development of Tetrahydrocannabivarin as a Treatment for Smokers","Inclusion Criteria:\n\n1. Be between the ages of 21 and 65;\n2. Smoke 10 or more combustible cigarettes per day;\n3. Have fewer than 3 months of smoking abstinence in the past year;\n4. Has self-reported ≥10 lifetime uses of cannabis products;\n5. Have self-reported recent (past 3-month) use of cannabis products;\n6. Agree to abstain from all other cannabinoid use during the study;\n7. Agree to abstain from all other medication use during the study, other than methods of birth control as listed in inclusion criteria for female participants;\n8. Agree to one of the following methods of birth control (if female), unless she or partner are surgically sterile: oral contraceptives, Contraceptive sponge, patch, double barrier, intrauterine contraceptive device, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, hormonal vaginal contraceptive ring, complete abstinence from sexual intercourse.\n\nExclusion Criteria:\n\n1. Have current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than nicotine;\n2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any other psychotic disorder;\n3. Have a score of 3 or greater on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or anytime during study participation;\n4. Have a positive urine screen for any substances, including cannabis\n5. Have a breathalyzer reading above 0.000 g\u002Fdl;\n6. Be pregnant, nursing, or planning to become pregnant while taking part in the study;\n7. Have a medical condition that may interfere with safe study participation;\n8. Have clinically significant abnormalities on the EKG;\n9. Have evidence of renal impairment, defined by an eGFR value of \\\u003C90 ml\u002Fmin;\n10. Have evidence of hepatic impairment, defined by a score of ≥5 points on the Child-Pugh assessment of liver function;\n11. Exceed Grade 2 laboratory or vital sign abnormalities, based on FDA Guidance Document \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\";\n12. Have past month use of cannabis or cannabis products;\n13. Have past month use of electronic nicotine delivery system (ENDS);\n14. Have use of any medications (other than methods of birth control as listed in inclusion criteria for female participants) within 14 days or 5 half-lives (whichever is longer) prior to study drug administration, and throughout the study, including medication for smoking cessation, any prescription, OTC, dietary supplements, herbal products, or vitamins;\n15. Have any other circumstances that, in the opinion of the investigators, would not be a good fit for study participation.","65 Years",{"count":210,"type":21},32,[24],"This study will randomize 32 non-treatment-seeking individuals who smoke cigarettes daily into a randomized, crossover, double-blind, placebo-controlled study testing the safety, tolerability, and initial efficacy of Δ9-tetrahydrocannabivarin (Δ9-THCV).",[27,29],[215,216,217,218,219],"smoking cessation","tobacco use disorder","cigarette smoking","THCV","Tetrahydrocannabivarin","2026-06-02",{"date":222,"type":37},"2026-06-09",{"date":224,"type":21},"2026-07",{"date":226,"type":21},"2028-05-31",{"name":228,"class":44},"University of California, Los Angeles",{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100625629","project-q-cue-based-treatment-intervention-to-promote-cessation-among-people-who-smoke-lightly-or-non-daily-100625629","NCT07425119","Project Q: Cue-based Treatment Intervention to Promote Cessation Among People Who Smoke Lightly or Non-daily","Feasibility of Cue-based Treatment Intervention to Promote Cessation Among People Who Smoke Lightly (≤10 Cigarettes Per Day) or Non-daily","Inclusion Criteria:\n\n* Age ≥18\n* Able to read and understand English or Spanish\n* Smoke 1-10 cigarettes\u002Fday on at least 4 days of the past two weeks for the last year\n* Willing to try quitting in next 30 days\n* Access to cell phone with texting capabilities\n\nExclusion Criteria:\n\n* Current participation in another smoking cessation study\n* Unable to provide consent\n* Refusal to abstain from e-cigarettes or other tobacco products\n* Use of medications affecting smoking cessation (e.g., Chantix, Wellbutrin)",{"count":237,"type":21},60,[57],"This study aims to test the feasibility and acceptability of a remotely delivered cue-based treatment intervention to promote smoking cessation among people who smoke lightly or non-daily. Secondary objectives include assessing preliminary efficacy on cessation and examining cue reactivity. Participants will be randomized to CBT only or CBT + cue-based treatment, with assessments at baseline, end-of-treatment, 6 months, and 12 months.",[27],[242,243,244],"Smoking cessation","Cue-based treatment","Cognitive Behavioral Therapy",{"date":193,"type":37},{"date":247,"type":21},"2026-06-30",{"date":249,"type":21},"2028-06",{"name":251,"class":44},"Duke University",{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":16,"sex":17,"minAge":132,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100589308","chatbot-for-online-support-groups-to-treat-tobacco-addiction-100589308","NCT06952725","Chatbot for Online Support Groups to Treat Tobacco Addiction","Intelligent Chatbot for Online Support Groups to Treat Tobacco Addiction","Inclusion Criteria:\n\n* Cigarette smokers (can also use e-cigarettes)\n* Ages 18-75 years\n* English speaking\n* Smart phone with unlimited data\n* 100 cigarettes lifetime\n* Prepared to quit smoking within 10 days of study start\n* Active text and email\n* Use of social media or group messaging\n* Home address provided\n* Contact information for a collateral provided\n* Setup of a GroupMe account for study\n\nExclusion Criteria:\n\n* No NRT health contraindications\n* 5+ cigarettes per day\n* Not an illicit drug user\n* Not a daily marijuana\u002Fcannabis user","75 Years",{"count":261,"type":21},120,[57],"Investigators will conduct a pilot RCT to test the efficacy of an intelligent chatbot to aid small, private, quit-smoking peer support groups. Participants will be randomized to an intervention arm (chatbot-enhanced support group), or a control arm (support group only). In the intervention arm (N=60), each support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). The intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so. In the control arm (N=60), the support groups will be connected to an automated message-posting bot running on a secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot. But both the intelligent chatbot and the automated message-posting bot will post a pre-written daily discussion topic to encourage participants to discuss issues known to facilitate tobacco cessation or group bonding.",[104,27],[266,267,268],"tobacco use addiction","online support group","chatbot","2026-05-20",{"date":271,"type":37},"2026-05-22",{"date":273,"type":21},"2026-12-01",{"date":275,"type":21},"2028-06-01",{"name":277,"class":44},"University of California, Irvine",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":285,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":309},"100640899","multilevel-intervention-for-ldct-lung-cancer-screening-and-smoking-cessation-among-african-americans-100640899","NCT07576595","Multilevel Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African Americans","Effectiveness of a Multilevel Integrated Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African Americans","Inclusion Criteria:\n\n* African American\n* 20+ pack years of smoking\n* eligible for or received LDCT screening\n* current smoker\n* English speaking\n\nExclusion Criteria:\n\n* N\u002FA","50 Years","80 Years",{"count":288,"type":21},250,[57],"This study aims to reduce disparities and the burden of lung cancer among African American smokers by supporting a Multiple-level intervention integrating lung cancer screening and smoking cessation (MILS), followed the NIH DEIA strategies using multilevel interventions that impact determinants of health and address health disparities at appropriate time points across the life course.",[292,27,29],"Lung Cancer Screening",[294,295,292,29,296,297,298,299],"African American","Health Disparities","Tobacco Use","Low-Dose Computed Tomography","LDCT","Behavioral Intervention","2026-05-07",{"date":302,"type":37},"2026-05-11",{"date":304,"type":37},"2025-04-17",{"date":306,"type":21},"2030-06",{"name":308,"class":44},"Louisiana State University Health Sciences Center in New Orleans",2,{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":178},"100636653","tubsis-20---tobacco-use-behavioral-support-and-intervention-system-100636653","NCT07568483","TUBSIS 2.0 - Tobacco Use Behavioral Support and Intervention System","Effectiveness of an Internet-based, Self-help, Asynchronized Behavioral Therapy With Mindfulness Approach for Adults With Tobacco Smoking or Vaping to Support Adults in Reducing Tobacco Smoking and Vaping in Switzerland and Türkiye","TUBSIS_2_0","Inclusion Criteria:\n\n* Age: 18 years or older\n* Smoking status:\n\nSmoked on ≥1 day in the past 30 days, and\u002For Smoked at least 100 cigarettes in lifetime\n\n* Internet access: Stable internet connection and access to a smartphone, tablet, or computer during interaction of the TUBSIS 2.0 web-based platform.\n* Language: Sufficient reading and listening comprehension in the study language (German, English or Turkish)\n* Contact: Valid email address and phone number (optional) for study communication, reminders and incentive payments\n* Consent: Provided electronic informed consent on TUBSIS 2.0 web-based platform which is developed and administrated by ISGF.\n* Study procedures: Agreement to randomization (intervention or control) and completion of study assessments at four time points (baseline, mid-intervention, post-intervention and 8-week follow-up)\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria are excluded.",{"count":319,"type":21},406,[57],"Background:\n\nTobacco smoking and vaping remains public health concern, with many adults continuing to experience difficulties accessing appropriate support for smoking cessation in Switzerland and Türkiye. Structural barriers, including stigma related to attempting to quit, limited financial and time resources, low awareness of the health risks associated with tobacco smoking- and vaping-reduce engagement with traditional services. TUBSIS 2.0 aims to address these access inequities by providing a fully remote, anonymous and free internet-based program tailored to diverse adult populations in both countries.\n\nObjectives:\n\nThe \"TUBSIS 2.0: An Adaptation Study of Tobacco Addiction Support Programme - TUBSIS for Tobacco Users in Switzerland and Türkiye\" project aims to support readiness to reduce or quit tobacco smoking\u002Fvaping, improve well-being and self-compassion and strengthen health-related behaviors. The intervention targets German-, English-, and Turkish-speaking adults and includes mindfulness-based strategies for quitting or reducing tobacco smoking and vaping. Motivation to cease tobacco smoking\u002Fvaping varies considerably across the lifespan. Younger individuals may perceive smoking\u002Fvaping cessation as unnecessary, often due to limited awareness of long-term health risks or a sense of invulnerability. In later adulthood, although addiction tends to be more deeply established, many individuals hesitate to attempt cessation because of concerns about the psychological and behavioral challenges associated with the process. It is therefore essential to provide individuals with support that helps them understand the cessation process, prepare for the challenges that can be expected and identify strategies that align with their psychological needs. Such strategies may include stress management and self-compassion practices that can be utilized before, during and after cessation attempts. TUBSIS 2.0 offers structured and accessible guidance to support this preparation by providing a clear, evidence-based pathway for individuals at different stages of readiness to change.\n\nMethods:\n\nTUBSIS 2.0 is a web-based, individual and asynchronous program consisting of eight modules delivered over four weeks. A total of 406 participants will be recruited and randomly assigned to either the intervention or control group. Data are collected anonymously at four measurement points (baseline, mid-term, post-term and 8-week follow-up) from participants. The program focuses on supporting participants' reducing or quitting tobacco smoking or vaping; to increase their readiness for smoking\u002Fvaping cessation, mental well-being, self-compassion and stress management with mindfulness strategies.\n\nWithin the Health Action Process Approach (HAPA), the process of behaviour change is conceptualised as a dynamic, non-linear process that progresses through motivational and volitional phases. TUBSIS 2.0 has been adapted to reflect this structure by integrating phase-specific components. These components include modules that enhance risk awareness and outcome expectancies, planning and self-regulation tools to support action initiation and mindfulness-based strategies that are embedded throughout all phases to strengthen self-efficacy and coping. By addressing these shifting needs across the change process, the programme provides a responsive and theory-driven pathway for reducing\u002Fquitting tobacco smoking or vaping.\n\nRelevance:\n\nTUBSIS 2.0 is highly relevant to public health priorities, as it provides a cost-effective, scalable and environmentally sustainable intervention that eliminates barriers commonly associated with traditional cessation services. By requiring no travel, printed materials or in-person appointments, the programme offers equitable access to adults across all age groups, genders and diverse migrant communities in Switzerland and Türkiye. Its multilingual and culturally adapted structure addresses significant service gaps for populations that are underserved or hesitant to seek conventional support. By reducing tobacco smoking- or vaping-related harm and facilitating early behavioural change, TUBSIS 2.0 has the potential to decrease long-term healthcare costs while expanding access to evidence-based digital prevention tools.",[27,139,323,324],"Vaping","Smoking Tobacco",[326,169,327,328,329],"smoking tobacco","web-based intervention","mindfulness","Health Action Process Approach","2026-04-30",{"date":332,"type":37},"2026-05-05",{"date":334,"type":37},"2025-11-15",{"date":336,"type":21},"2026-08-31",{"name":338,"class":44},"University of Zurich",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":16,"sex":17,"minAge":132,"maxAge":208,"enrollmentInfo":346,"targetDuration":4,"studyType":348,"phases":4,"briefSummary":349,"conditions":350,"keywords":361,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":309},"100564051","computer-game-qualitative-and-megeeg-assessment-of-serotonergic-psychedelics-100564051","NCT06624137","Computer Game, Qualitative, and MEG\u002FEEG Assessment of Serotonergic Psychedelics","Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects","Inclusion Criteria:\n\n* Participation in approved clinical protocol at Yale University involving potential administration of serotonergic psychedelics\n* Absence of pre-existing psychotic symptoms\n\nExclusion Criteria:\n\n* Current intoxication based on self-report\n* Any neurological, medical or developmental problem that is known to impair cognition significantly based on self-report\n* History of seizures based on self-report\n* Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia (specific to those who will participate in MRI)",{"count":347,"type":21},200,"OBSERVATIONAL","This is an observational study which does NOT directly administer a psychedelic substance but rather recruits participants who are already participating in another clinical trial in which they may receive a serotonergic psychedelic. The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine\u002FDMT, Lystergic Acid Diethylamide\u002FLSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are:\n\n1. Do serotonergic psychedelics cause the brain to rely on new information more than previously learned information while under the influence? What about 1 day, 5-14 days, and 4-6 weeks after use?\n2. Do serotonergic psychedelics cause long-lasting side-effects in how people perceive (see, hear, feel, etc.) the world and how easily people change their beliefs?\n3. How does the brain's electrical activity change after using serotonergic psychedelics? How does the balance between excitation and inhibition change while under their effect?\n4. Can changes in how the brain uses information predict who will benefit from a psychedelic and who will have side effects from psychedelics?\n\nResearchers will compare with people given placebos to see what changes in brain processing are unique to serotonergic psychedelics.\n\nParticipants will have the opportunity to do some combination of the following:\n\n1. Online computer assessments consisting of games and questionnaires that probe how participants think.\n2. Magnetoencephalography (MEG) or electroencephalography (EEG) with eyes closed and with repeated clicks, images, or sensations delivered.\n3. A magnetic resonance imaging (MRI) scan.\n4. Semi-structured qualitative interviews about their experience after taking a serotonergic psychedelic recorded via Zoom.",[351,352,353,354,355,356,357,358,27,359,360],"OCD","Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)","Healthy Volunteer","Migraine","PTSD","PTSD - Post Traumatic Stress Disorder","Addiction","Obsessive Compulsive Disorder (OCD)","Opioid Use Disorder",[362,363,364,365,366,367,368,369,370,371,372],"Psilocybin","DMT","N,N-dimethyltryptamine","Ayahuasca","Lysergic acid diethylamide","LSD","5-MeO-DMT","O-methyl-bufotenin","eeg","meg","5-Methoxy-N,N-Dimethyltryptamine","2026-04-27",{"date":375,"type":37},"2026-05-01",{"date":377,"type":37},"2024-12-12",{"date":379,"type":21},"2028-05",{"name":381,"class":44},"Yale University",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":22,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":178},"100484386","phase-4-beta-adrenergic-modulation-of-drug-cue-reactivity-100484386","NCT05587361","Beta-Adrenergic Modulation of Drug Cue Reactivity","Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms","Inclusion Criteria:\n\n1. Generally healthy\n2. Age 21-60\n3. Right-handed using a three-item scale\n4. Daily smoker of ≥ 5 cigarettes\u002Fday delivering 0.5 mg nicotine (FTC)\n5. Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months\n6. Afternoon expired Carbon Monoxide (CO) concentration ≥ 6 ppm and\u002For morning urinary cotinine \\>100 ng\u002Fml\n7. Must identity at least 4 different smoking locations used in a typical week\n8. Able to read and understand English\n\nExclusion Criteria:\n\n1. Inability to attend all required sessions\n2. Significant health problems that would preclude active participation\n3. Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape)\n4. Current use of psychoactive medications\u002Fdrugs as indicated by self-report or urine screen\n5. Positive breath alcohol concentration\n6. Pregnant, breastfeeding, or planning to become pregnant during the course of the study (females)\n7. Problems with vision that cannot be corrected with contacts or glasses\n8. Current regular use of smokeless tobacco, smoking cessation medications, or other nicotine containing products (e.g. electronic cigarettes)\n9. Current use of beta-adrenergic medications (e.g. beta-blockers) or other blood pressure medications\n10. Systolic blood pressure \\\u003C 90 mmHg or diastolic blood pressure \\\u003C 60 mmHg (sitting or standing)\n11. Abnormal EKG\n12. Presence of severe anemia\n13. Presence of electrolyte imbalance that could impact blood pressure\n14. Presence of any other contraindications for propranolol or nicotine patch (e.g. cardiovascular disease, bronchial asthma, prior allergic reactions, diabetes)","60 Years",{"count":391,"type":21},80,[100],"This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.",[27,139,32],{"date":396,"type":37},"2026-04-28",{"date":398,"type":37},"2024-11-26",{"date":400,"type":21},"2027-03-31",{"name":402,"class":44},"University of Oklahoma",{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":412,"conditions":413,"keywords":418,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":178},"100593048","emotional-brain-training-for-addiction-medicine-treatment---a-pilot-study-100593048","NCT07001371","Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study","Inclusion Criteria:\n\n* Age 18 years old or older\n* Patient can speak and read English\n* Patient who receives regular MAT care at SAC Health\n* Patients who have regular and reliable cellular and\u002For reliable internet connection\n* Patients who are willing to spend average of 25 minutes per day and attend weekly group meetings\n* Patients willing to actively participate in group sessions\n* Opioid use disorder, at least in early remission\n* Alcohol use disorder, at least in early remission\n* Methamphetamine use disorder, at least in early remission\n* Cocaine use disorder, at least in early remission\n* Anxiolytic use disorder, at least in early remission\n* Cannabis use disorder\n* Tobacco use disorder\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* Patient does not speak or read English\n* Patients who do not seek regular MAT care at SAC Health\n* Patients with inconsistent or no access to cellular or internet connection\n* Any disorder that is uncontrolled\n* Any substance use disorder not in at least early remission\n* Any patient with complications related to use disorder\n* Patients enrolled in the Coachella Valley Rescue Mission patients a part of SAC Health\n* Anyone who, in the opinion of the investigators, would be unable to participate in an 8-week trial",{"count":410,"type":21},54,[57],"The goal of this clinical trial is to determine whether Emotional Brain Training (EBT), a behavioral modification method, can help manage stress and health problems related to addiction. EBT teaches skills to deactivate harmful circuits (automatic reactions) and activate healing circuits to quickly shift mood from negative to positive. Participants in the EBT group will receive focused, intensive instruction on using these skills to rewire unwanted brain circuits, with the aim of achieving lasting improvements in emotional health and quality of life. The study will assess whether EBT is an effective tool when added to standard of care (SOC), which includes medications for addiction treatment (MAT).\n\nResearchers will compare changes in stress, anxiety, and cravings after 8 weeks of EBT plus SOC versus SOC alone.\n\nParticipants:\n\n* will either continue receiving standard treatments (SOC) at the Addiction Recovery Clinic (ARC) at SAC Health in San Bernardino\n* or receive both EBT and SOC at ARC\n* in the SOC group will continue monthly visits at ARC and weekly counseling\n* in the EBT plus SOC group will continue monthly visits and weekly counseling at ARC, along with weekly EBT group sessions by telephone\n* will complete online assessments at weeks 0, 4, and 8 Upon completion of the study, all participants will resume SOC",[414,415,360,27,416,417],"Cannabis Use Disorder","Stimulant Use Disorder","Alcohol Use Disorder","Sedative, Hypnotic, or Anxiolytic Use Disorders",[419,420],"early remission","sustained remission","2026-04-21",{"date":423,"type":37},"2026-04-23",{"date":425,"type":21},"2026-08",{"date":427,"type":21},"2027-08",{"name":429,"class":44},"Loma Linda University",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":443,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":309},"100615459","phase-2-accelerated-dtms-smoking-cessation-100615459","NCT07292883","Accelerated dTMS Smoking Cessation","Accelerated Deep Transcranial Magnetic Stimulation for Smoking Cessation","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. Tobacco use disorder as assessed by DSM-5;\n3. Fagerstrom Test of Nicotine Dependence (FTND) ≥ 4;\n4. Reported motivation to quit within 30 days as assessed using the Contemplation Ladder score of ≥ 7;\n5. Must sign and date the informed consent form;\n6. Stated willingness to comply with all study procedures.\n7. Able to communicate in English.\n\nExclusion Criteria:\n\n1. Reported smoking abstinence in the 3 months preceding screening visit;\n2. Current use of other smoking cessation aids;\n3. Contraindication to rTMS;\n4. Pregnancy, trying to become pregnant or breastfeeding;\n5. Current or recent history of cerebrovascular disease;\n6. Unstable major psychiatric disorder(s) (i.e. Axis I Disorders) that would prevent participation in the study at PI (or its delegate) discretion;\n7. Serious current or personal history of medical condition\u002Fdisease (neurological disorders, brain lesions, multiple sclerosis, head trauma, loss of consciousness, hearing loss, etc.) preventing same inclusion as per PI (or its delegate) discretion;\n8. Current, personal history or family history of seizures;\n9. Concomitant use of medication that lowers seizure threshold, such as clozapine;\n10. Concomitant use of more than 2 mg lorazepam (or an equivalent) or any anticonvulsants.",{"count":438,"type":21},40,[24],"The goal of this clinical trial is to examine whether a 5-day course of bilateral accelerated deep transcranial magnetic stimulation (aTMS) is a feasible treatment to help adults (18-65) with Tobacco Use Disorder to quit smoking. This study aims to enroll 30-40 participants and will examine treatment tolerability, treatment acceptability, participant retention, and adherence to scheduled treatment sessions.\n\nThere are two key objectives and hypotheses:\n\nObjective 1: To evaluate whether a 1-week course of bilateral aTMS (4 sessions per day for 5 days) is feasible and tolerable as a smoking cessation treatment.\n\nHypothesis 1: Feasibility will be demonstrated by acceptable tolerability, acceptability, retention, and adherence, with a practical target of 30 out of 40 participants completing the treatment.\n\nObjective 2: To explore how aTMS affects smoking outcomes, including:\n\n* Point-prevalence abstinence at end of treatment and at Weeks 3, 5, and 9.\n* Prolonged\u002Fcontinuous abstinence at Weeks 13 and 26.\n* Craving, cigarettes per day, and dependence severity. Hypothesis 2: Participants will show improvements on these outcomes from post-treatment through follow-up.",[27,442],"Addiction Nicotine",[444,215,445,446],"addiction","Transcranial Magnetic Stimulation","Accelerated Repetitive Transcranial Magnetic Stimulation","2026-04-15",{"date":421,"type":37},{"date":450,"type":37},"2026-02-24",{"date":452,"type":21},"2028-01-01",{"name":454,"class":44},"Waypoint Centre for Mental Health Care",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":208,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":178},"100628840","auricular-stimulation-for-nicotine-withdrawal-in-psychiatric-inpatients-100628840","NCT07466875","Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients","The Efficacy of Auricular Acupressure Combined With Nicotine Replacement Therapy on Nicotine Craving, Withdrawal Symptoms and Anxiety Levels in Psychiatric Inpatients: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Psychiatric inpatients aged 18 to 65 years.\n* Diagnosed with a mental disorder according to ICD-10-CM criteria.\n* History of daily smoking within the past six months (Fagerström Test for Nicotine Dependence \\[FTND\\] score ≥ 2).\n* Experiencing nicotine withdrawal symptoms due to mandatory smoking cessation upon admission (Minnesota Tobacco Withdrawal Scale \\[MNWS\\] baseline score ≥ 5).\n* Agree to and comply with the standard-of-care Nicotine Replacement Therapy (NRT) provided by the hospital.\n* Capable of understanding the study procedures and providing written informed consent\n\nExclusion Criteria:\n\n* Presence of severe skin infection, open wounds, or lesions on the auricle (outer ear).\n* Severe coagulation disorders or currently taking high-dose anticoagulants (due to potential risk of bleeding or irritation).\n* Pregnant or breastfeeding women.\n* Significant language barriers or cognitive impairment that prevents completion of assessment scales or adherence to study protocols.\n* History of receiving auricular therapy for smoking cessation within the past three months.",{"count":237,"type":21},[57],"The goal of this clinical trial is to evaluate the feasibility and preliminary effectiveness of auricular acupressure (ear seeds) combined with nicotine replacement therapy (NRT) in psychiatric inpatients (both male and female, aged 18-65) who are forced to abstain from smoking due to the smoke-free environment of the inpatient ward. The main questions it aims to answer are:\n\n* Does auricular acupressure significantly reduce the severity of nicotine withdrawal symptoms compared to standard care?\n* Can auricular acupressure effectively lower nicotine craving and anxiety levels in patients during their mandatory abstinence? Researchers will compare the experimental group (NRT plus active auricular acupressure) to a control group (NRT plus sham auricular acupressure) to see if the addition of ear point stimulation provides better relief for withdrawal distress.\n\nParticipants will:\n\n* Receive standard nicotine replacement therapy (NRT) as prescribed by their physician.\n* Be randomly assigned to receive either Vaccaria segetalis seeds or sham materials on specific ear acupuncture points.\n* Be instructed to press the beads 3 times daily to stimulate the points for a period of 4 weeks.\n* Complete standardized assessments (MNWS, HAMA, and craving scales) at baseline and multiple time points during the intervention.",[139,466,27,467,468],"Nicotine Withdrawal","Anxiety","Mental Disorders","2026-04-06",{"date":471,"type":37},"2026-04-13",{"date":473,"type":37},"2026-03-23",{"date":475,"type":21},"2027-12-31",{"name":477,"class":44},"Chiao-Chiao Liao",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":208,"enrollmentInfo":485,"targetDuration":4,"studyType":22,"phases":486,"briefSummary":487,"conditions":488,"keywords":490,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":178},"100532841","phase-2-cannabidiol-for-reducing-cigarette-use-100532841","NCT06218056","Cannabidiol for Reducing Cigarette Use","Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use","Inclusion Criteria:\n\nThe investigators will study equal numbers of males and females betweeen 18 - 65 years of age who have Tobacco Use Disorder and express a desire for smoking cessation. Participants will be recruited from the clientele base at Cri-Help Treatment Center in North Hollywood, CA, where the investigators have a long-standing relationship and where the investigators have conducted other research protocols. This study will be conducted at Cri-Help Treatment Center.\n\nParticipants will not be recruited from the general population for this study because common use of cannabis in the greater Los Angeles area would confound measurements of CBD, interfering with evaluation of the association of plasma level from treatment with efficacy. This problem is avoided in studying participants who are receiving treatment at a facility where cannabis use is not allowed.\n\nThe investigators will include all racial and ethnic groups. Based on the population of the surrounding communities in the Los Angeles region, the investigators anticipate a racial and ethnic makeup of approximately 26% White, 9% Black\u002FAfrican American, 49% Hispanic\u002FLatino, 14% Asian American, and 2% multi-racial\u002Funknown. These percentages align with our recent studies.\n\nSmoking cigarettes and at least moderate nicotine dependence, as indicated by smoking 5 or more cigarettes per day and\u002For a score of at least 4 on the Fagerström Test for Nicotine Dependence are inclusion criteria. Although vaping is popular and a high proportion of participants who vape also report cigarette smoking (58%), the investigators will exclude participants who vape nicotine. Vaping is not allowed at Cri-Help, Inc.\n\nExclusion Criteria:\n\n* Physiological dependence on alcohol or any drug, requiring medical detoxification and\u002For showing signs of acute withdrawal symptoms from opioids, alcohol or benzodiazepines.\n* Treatment of Opioid Use Disorder with buprenorphine or methadone to avoid potential drug-drug interactions. CBD interacts with CYP3A. Opioid drugs metabolized by cytochrome P450 (CYP450), and cytochrome P450 isoenzyme CYP3A4 (CYP3A4) in particular, include fentanyl, methadone, oxycodone, and buprenorphine.\n* Meeting DSM-5 criteria for schizophrenia, Bipolar I disorder, psychotic disorder, having active suicidal ideation, or suicide attempt in the past 12 months. NOTE: Participants with other psychiatric conditions, such as major depression, generalized anxiety, dysthymia, social phobia or specific phobia can enroll if they are clinically stable.\n* AIDS or current HIV medication treatment with antiviral and\u002For non-antiviral therapy (due to the interaction of CBD with antiviral therapy).\n* Clinically significant abnormalities on EKG (such as evidence of arrhythmia or MI).\n* Clinically significant cardiovascular, hematologic, hepatic, renal, neurological, or endocrine abnormalities \\[specific exclusion criteria: AST greater than or equal to 3Xs ULN, Bilirubin greater or equal to 1.5 X ULN, Prothrombin time\u002FInternational Normalized Ratio (INR) \\> 1.5.\n* Pregnancy and\u002For lactation. Contraception methods required at time of enrollment, and throughout the duration of the study medication period include abstinence, oral contraceptives, depot contraceptives, condom with spermicide, cervical cap with spermicide, diaphragm with spermicide, intrauterine device, surgical sterilization (e.g. tubal ligation, vasectomy).\n* Because of evidence that CBD affects ovarian function in rats, women with values outside the reference ranges on a hormonal battery \\[estradiol, follicle- stimulating hormone, free thyroxine index, luteinizing hormone, prolactin, total T3 and total T4, thyroid-stimulating hormone\\], followed by an abnormal ovarian ultrasound finding will be excluded.\n* Based on data obtained using Epidiolex® (CBD) oral solution label section 7, \"Drug Interactions\", the investigators will exclude participants who are taking the following medications: a) strong inducers of CYP3A4 or CYP2C19, which may decrease CBD plasma levels; and b) substrates of UGT1A9, UGT2B7, CYP2B6, CYP2C19 due to the potential of CBD to inhibit enzyme activity.",{"count":261,"type":21},[24],"The goal of this research is to evaluate the efficacy of cannabidiol (CBD) in reducing cigarette smoking. Although there are safe and effective treatments for smoking cessation, not everyone who attempts smoking cessation is successful, even with these treatments. Relapse rates are high, leaving a need for new approaches. Despite justification to evaluate CBD for this indication, human research on the topic is scant. Larger, more extended studies are warranted and essential.\n\nThe investigators will recruit participants from CRI-Help, Inc., a substance abuse treatment program in North Hollywood, where residents who indicate the desire to stop smoking are prohibited from using other cannabis products which would affect recruitment.\n\nThe aims of this study are:\n\n1. Evaluate the effects of CBD on nicotine intake.\n2. Exploratory Aims. Measure plasma concentrations of CBD, N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG) at baseline and day 7.\n\nParticipants who meet eligibility criteria will take part in a 56-day treatment phase during which they receive the study medication under supervision (CBD or placebo twice daily) and complete questionnaires on side effects, withdrawal, craving and mood symptoms. Blood, breath, and urine tests will also be performed throughout the study. Participants who complete the treatment will also be assessed at 1-month and 3-month follow up visits.",[27,489,104],"Tobacco Smoking",[491,27,29],"Cannabidiol",{"date":471,"type":37},{"date":494,"type":37},"2024-10-31",{"date":496,"type":21},"2026-12-31",{"name":228,"class":44},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":16,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":178},"100583963","phase-3-cannabis-tobacco-co-use-treatment-study-100583963","NCT06883162","Cannabis-Tobacco Co-Use Treatment Study","Randomized Controlled Trial of Varenicline to Treat Tobacco and Cannabis Co-Use (RECLAIM)","RECLAIM","Inclusion criteria:\n\n1. Ages 18 and over (no upper age limit)\n2. Must smoke at least 5 tobacco cigarettes per day on at least 20 out of the past 30 days for the past 3 months\n3. Must express interest in quitting tobacco\n4. Must express interest in cannabis reduction and\u002For cessation\n5. Must submit a positive instant-read test for cotinine and cannabis prior to enrollment\n6. Must self-report cannabis use (THC-dominant products) on at 3 days per week out of the past 30 days\n7. Must be willing to take varenicline or placebo for 12 weeks\n8. Must reside in South Carolina\n\nExclusion criteria:\n\n1. Any significant or acutely unstable medical, psychiatric, or substance use problem (including clinically significant disorders) that would contraindicate research, interfere with safety, compromise data integrity, or preclude consistent study participation\n2. Pregnant or trying to become pregnant\n3. Use of medications with smoking cessation efficacy\n4. Regular use of e-cigarettes or other tobacco products (\\\u003C10 days in the past month)",{"count":347,"type":21},[508],"PHASE3","The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence and cannabis reduction or abstinence. All participants will also receive counseling and access to online treatment modules during a quit attempt for cigarettes and a reduction attempt for cannabis. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed.\n\nTo qualify, participants must be 18 or older, live in South Carolina, use cigarettes and cannabis, and are interested in quitting cigarettes and reducing cannabis.",[27,511,512,414,62],"Tobacco Use Cessation","Cannabis Use","2026-04-02",{"date":515,"type":37},"2026-04-03",{"date":517,"type":37},"2025-05-06",{"date":519,"type":21},"2029-01-01",{"name":152,"class":44},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":286,"enrollmentInfo":528,"targetDuration":4,"studyType":22,"phases":530,"briefSummary":531,"conditions":532,"keywords":533,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":178},"100598752","quit-smoking-study-for-native-hawaiians-100598752","NCT07075575","Quit-Smoking Study for Native Hawaiians","Smoking Cessation Among Native Hawaiians: A Test of Pharmacotherapies and Group-Based Counseling","Inclusion Criteria:\n\n* Self-identifies as full or part Native Hawaiian\n* Between the ages of 18 and 80 years, inclusive, at eligibility screening\n* Currently smoking ≥5 cigarettes per day (self-report) at eligibility screening\n* Has smoked more than 100 cigarettes in his\u002Fher lifetime (self-report)\n* Affiliated with one of three (3) designated public housing complexes at which the intervention will be delivered: Kalihi Valley Homes, Kuhio Park Terrace, Mayor Wright Housing\n* Willing to make a smoking cessation attempt the day after the first study visit (i.e., date of consent)\n* Willing to engage in use of nicotine replacement therapy gum (NRT gum) and\u002For smoking cessation-focused cognitive-behavioral group therapy (CBGT)\n* Participant must agree to not use any form of pharmacotherapy (i.e., prescription medication or any form of nicotine replacement therapy) to try to quit smoking during the 12-week study period, except as specifically assigned to his or her study condition and distributed by the research team\n* Participant must agree to not use other tobacco or nicotine products (e.g., cigars, little cigars, electronic cigarettes, nicotine pouches) during the 12-week study period\n* Participant must agree to not smoke or vape cannabis (i.e., marijuana) during the 12- week study period\n* Participant must agree to not use other illicit drugs, including prescription opioid medications, during the 12-week study period\n* Participant must be able to speak, read, and write English\n* Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent\n\nExclusion Criteria:\n\n* Pregnant or nursing, or planning to become pregnant or breastfeed in the next three (3) months\n* Use of pharmacotherapy (i.e., prescription medication or any form of nicotine replacement therapy) to try to quit smoking in the 30 days prior to eligibility screening\n* Use of other tobacco or nicotine products (e.g., cigars, little cigars, electronic cigarettes, nicotine pouches) in the 30 days prior to eligibility screening\n* Use of smoked or vaped cannabis (i.e., marijuana) in the 30 days prior to eligibility screening\n* Use of other illicit drugs, including prescription opioid medications, in the 30 days prior to eligibility screening",{"count":529,"type":21},75,[57],"This study aims to help Native Hawaiian adults quit smoking by testing two common methods: nicotine gum and group-based counseling. Participants will be assigned to one of three groups: (1) nicotine gum only, (2) group counseling only, or (3) a combination of both. The study will take place at public housing sites on O'ahu. Researchers will check if these approaches-alone or in combination-can support people in successfully quitting smoking. The goal is to find out which method works best and is most acceptable in this community.",[27,29],[534,242,111,535,32,104],"Native Hawaiian","Nicotine gum","2026-03-29",{"date":538,"type":37},"2026-03-31",{"date":540,"type":21},"2026-04-01",{"date":542,"type":21},"2028-04-01",{"name":544,"class":44},"University of Hawaii",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":16,"sex":17,"minAge":132,"maxAge":208,"enrollmentInfo":552,"targetDuration":4,"studyType":22,"phases":554,"briefSummary":555,"conditions":556,"keywords":558,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":565,"leadSponsor":567,"locationsCount":178},"100629434","effects-of-nicotine-dependence-on-multidimensional-health-outcomes-100629434","NCT07474623","Effects of Nicotine Dependence on Multidimensional Health Outcomes","The Relationship Between Nicotine Addiction Level and Respiratory Muscle Strength, Functional Capacity, Cognitive Functions, Pain, Quality of Life, Physical Activity Level, and Sleep Quality","Inclusion Criteria:\n\n* Regular cigarette use for at least the past 6 months\n* No history of respiratory, cardiovascular, or neurological\u002Fpsychiatric disease\n* No recent history of surgery or trauma that could affect respiratory muscles\n* No current acute infection (especially upper or lower respiratory tract infections)\n\nExclusion Criteria:\n\n* Presence of chronic respiratory diseases such as COPD or\n* History of cardiovascular disease\n* Diagnosed neurological or psychiatric disorders\n* history of surgery or trauma affecting the respiratory muscles within the last 3 months\n* Pregnancy or suspected pregnancy",{"count":553,"type":21},212,[57],"Nicotine, a major toxic component of cigarette smoke, together with carbon monoxide (CO), constitutes a significant environmental exposure with systemic effects. Beyond its addictive potential, chronic nicotine exposure may induce inflammation, oxidative stress, tissue hypoxia, and autonomic imbalance, potentially impairing respiratory muscle strength, functional capacity, and overall physical performance. Additionally, nicotine dependence has been associated with sleep disturbances, cognitive dysfunction, altered pain perception, and reduced quality of life.\n\nAlthough previous studies have examined individual effects of smoking on specific health outcomes, research addressing these multidimensional impacts within a comprehensive framework remains limited. Therefore, this study aims to investigate the relationship between nicotine dependence level and respiratory muscle strength, functional capacity, cognitive functions, pain, quality of life, physical activity level, and sleep quality, in order to provide a more holistic understanding of the clinical consequences of nicotine dependence.",[27,557],"Nicotine Dependence, Cigarettes",[139,559,560],"Respiratory Muscle Strength","Quality of Life","2026-03-11",{"date":563,"type":37},"2026-03-16",{"date":447,"type":21},{"date":566,"type":21},"2027-07-15",{"name":568,"class":44},"Izmir Democracy University",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":178},"100627968","facilitation-to-increase-tobacco-treatment-100627968","NCT07455526","Facilitation to Increase Tobacco Treatment","External Facilitation to Expand Reach of Tobacco Treatment to SMI Veterans","FITT","Inclusion Criteria:\n\nProviders:\n\n* VA Maryland Health Care System patient care providers serving Veterans in Critical Time Intervention, Psychosocial Rehabilitation and Recovery Center, Mental Health Integrative Case Management, or outpatient psychiatry clinics\n\nVeterans receiving direct letters:\n\n* Had an appointment in VA Maryland Health Care System, Critical Time Intervention, Psychosocial Rehabilitation and Recovery Center, Mental Health Integrative Case Management, or outpatient psychiatry clinics in the last 30 days\n* Diagnosed with a serious mental illness\n* Positive tobacco use screen\n* Appointment scheduled with an outpatient psychiatric prescriber in the next 30 days\n\n  * Of note, study staff are not directly recruiting Veterans for this implementation intervention component\n\nVeteran chart review:\n\n* All Veterans actively enrolled in VAMHCS medical facilities with at least one encounter during a given period with available smoking health factor data\n\n  * Of note, study staff are not directly recruiting veterans for this data analysis\n\nExclusion Criteria:\n\nProviders:\n\n* None\n\nVeterans receiving direct letters:\n\n* Active prescription for bupropion, varenicline, or any nicotine replacement therapy",{"count":578,"type":21},65,[57],"Smoking disproportionally impacts Veterans, and VA spends $2.7 billion annually on smoking-related health conditions. Veterans with serious mental illness (SMI) smoke tobacco products at triple the rate of Veterans without any mental illness and die 10-15 years earlier as a result. SMI Veterans who smoke want to quit and FDA-approved tobacco cessation medications are safe, effective, and readily available in VA. However, mental health providers are hesitant to treat smoking and just 11-18% of Veterans with SMI who smoke receive tobacco medication. External facilitation is an effective implementation strategy that can overcome barriers to integrating evidence-based treatment into routine clinical practice. In collaboration with local and operational partners, the proposed CDA-2 will evaluate and refine an external facilitation strategy to improve tobacco medication prescribing in VA SMI clinics. This proposal aligns with VA priorities to enhance timely access to care and improve Veteran outcomes.",[582,27],"Serious Mental Illness",[584,585,216,586,587,588,589,590],"veterans health services","mental health services","delivery of health care, integrated","attitude of health personnel","qualitative research","implementation science","mental disorders","2026-03-02",{"date":593,"type":37},"2026-03-06",{"date":595,"type":21},"2026-10-01",{"date":597,"type":21},"2031-10-01",{"name":121,"class":122},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":259,"enrollmentInfo":606,"targetDuration":4,"studyType":22,"phases":608,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":178},"100494854","phase-2-neuroimaging-correlates-and-feasibility-of-transcranial-magnetic-stimulation-tms-to-improve-smoking-cessation-outcomes-in-veterans-with-comorbid-ptsd-100494854","NCT05723588","Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD","TMS-STOP","Inclusion Criteria:\n\n* Is a US Veteran\n* Meets DSM-5 criteria for tobacco use disorder\n* Is between the ages of 18 and 75\n* Smokes an average of 10 cigarettes per day for the past 6 months, with carbon monoxide (CO) level \\> 6 ppm\n* Is willing to attempt smoking cessation\n* Meets DSM-5 criteria for current PTSD diagnosis\n* Speaks, reads and writes English\n* Is willing to sign a Duke consent for those portions of the study that occur at Duke\n* Has been stable on psychotropic medications for at least three months\n\nExclusion Criteria:\n\n* Has had a substance use disorder other than tobacco in the preceding 3 months\n* Has a history of myocardial infarction in the past 6 months or has another contraindication to NRT\n* Has a contraindication to TMS or MRI\n\n  * Personal or family history of a seizures or epilepsy\n  * History of neurological condition that increases the risk of seizures including stroke or transient ischemic attack, cerebral aneurysm, or severe traumatic brain injury from a penetrating head injury, loss of consciousness \\> 20 minutes at time of traumatic injury, requiring an anticonvulsant medication for seizures, and\u002For found to have encephalomalacia on baseline MRI\n  * Structural brain lesion, or prior brain surgery\n  * Ferromagnetic metal in head (including shrapnel)\n  * Implanted devices that may be affected by MRI or TMS (pacemaker, medication pump, cochlear implant, implanted deep brain stimulator)\n  * Is pregnant (to be determined at Duke)\n* Is unable to complete study procedures\n* Is currently prescribed bupropion and\u002For varenicline\n* Uses other forms of nicotine such as cigars, pipes, chewing tobacco, or vaping\n* Is unable to provide informed consent due to a major neurocognitive disorder or other reason\n* Meets criteria for a primary psychotic disorder or current manic episode\n* Is currently imprisoned or psychiatrically hospitalized\n* Has previously received rTMS",{"count":607,"type":21},50,[24],"Tobacco use is the number one preventable cause of the death in the United States, and is high among US Veterans, and those who have experienced trauma are more likely to smoke. Despite the efficacy of current evidence-based treatments for smoking cessation, there is a critical need for alternative treatments. This project seeks to evaluate the feasibility and effectiveness of a smoking cessation treatment for Veterans with posttraumatic stress disorder (PTSD) who smoke. The treatment combines smoking cessation counseling, nicotine replacement therapy (e.g., nicotine gum), and repetitive transcranial magnetic stimulation (rTMS). rTMS is a noninvasive brain stimulation treatment that has been cleared by the Food and Drug Administration for smoking cessation in adults.",[27],[612,103],"Tobacco use cessation","2026-02-13",{"date":615,"type":37},"2026-02-18",{"date":617,"type":37},"2023-10-31",{"date":619,"type":21},"2027-11-01",{"name":121,"class":122},{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":16,"sex":17,"minAge":628,"maxAge":53,"enrollmentInfo":629,"targetDuration":4,"studyType":22,"phases":631,"briefSummary":632,"conditions":633,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":641,"locationsCount":178},"100608228","mobile-health-mhealth-application-for-smoking-cessation-among-adolescents-in-indonesia-100608228","NCT07198828","Mobile Health (mHealth) Application for Smoking Cessation Among Adolescents in Indonesia","Development and Evaluation of a Mobile Health (mHealth) Application for Smoking Cessation Among Adolescents in Indonesia: A Mixed Methods Randomized Controlled Trial","Inclusion Criteria:\n\n1. Phase 1 (Qualitative Study):\n\n   * Adolescent smokers aged 13-15 years\n   * Smoking at least one cigarette or vaping once per week\n   * Key informants: teachers, parents, peers, healthcare workers with relevant experience\n2. Phase 3 (RCT):\n\n   * Adolescents aged 13-15 years\n   * Smoking at least 1 cigarette in the past week\n   * Own smartphone with internet access\n   * Living in Padang City during study period\n   * Willing to participate until study completion\n   * Desire to quit smoking\n\nExclusion Criteria:\n\nPhase 3 (RCT):\n\n* Currently using other smoking cessation apps or programs\n* Planning to change schools or relocate outside Padang during study period\n* Have severe psychiatric or medical conditions requiring intensive treatment\n* Unable to use smartphone applications due to literacy or technical limitations","13 Years",{"count":630,"type":21},110,[57],"This mixed-methods study develops and evaluates a mobile health (mHealth) application for smoking cessation among Indonesian adolescents aged 13-15 years. The study uses a sequential exploratory approach with three phases: (1) qualitative research to inform app design; (2) app development using Rapid Application Development (RAD) model; and (3) a single-blind, two-arm randomized controlled trial comparing the mHealth intervention to paper-based materials. The intervention is grounded in the Unified Theory of Acceptance and Use of Technology (UTAUT2) and Transtheoretical Model (TTM). Primary outcome is smoking abstinence at 1-, 3-, and 6-month follow-ups measured through self-report questionnaires.",[27,29,634],"Adolescent Smoking","2026-02-02",{"date":637,"type":37},"2026-02-04",{"date":639,"type":21},"2026-03-01",{"date":336,"type":21},{"name":642,"class":44},"Gadjah Mada University",{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":259,"enrollmentInfo":650,"targetDuration":4,"studyType":22,"phases":651,"briefSummary":652,"conditions":653,"keywords":654,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":45},"100498153","effects-of-mindfulness-meditation-in-virtual-reality-on-craving-and-smoking-cessation-100498153","NCT05766553","Effects of Mindfulness Meditation in Virtual Reality on Craving and Smoking Cessation","VIREAMIND","Inclusion Criteria:\n\n* Any patient consuming 10 to 40 cigarettes per day\n* Woman or man aged 18 to 75 inclusive\n* Substance use disorder according to the DSM5 classification\n* Benefit from social security or benefit from it through a third party in accordance with French law on research involving the human person\n* Having signed the informed consent form after having received written information.\n\nExclusion Criteria:\n\n* Disabling cognitive disorders\n* Patient under 18 or over 75 years old.\n* Patient with a psychological disorder or a psychiatric pathology requiring specialized follow-up\n* Patient with addiction to another product.\n* Cardiological pathologies that could compromise the participation of patients, detected by an ECG (only for patients who will be randomized in the experimental group).\n* Advanced pulmonary, renal, and hepatic diseases, or any unstable and serious medical conditions that could compromise the patient's participation in the study, subject to the judgment of the doctor\n* Pregnant or breastfeeding woman\n* Simultaneous participation in another trial\n* Employee of the investigator or of the clinical trial site\n* Patients protected by law\n* Patients who do not speak the French language\n* People not covered by state health insurance\n* Patients who in the opinion of the investigator are unable to complete the questionnaires\n* Patient claustrophobic or anxious about using the cabin\n* Patient allergic to a molecule present in nicotine substitutes",{"count":347,"type":21},[57],"Investigators seek to propose a non-drug therapeutic alternative, namely a mindfulness meditation protocol based on virtual reality training in order to induce progressive modifications of various indicators of craving.\n\nThe study hypothesis is that the practice of mindfulness meditation in a virtual reality environment reduces the craving induced by cues and stress and therefore ultimately smoking relapse.\n\nThe main objective of the protocol will be to demonstrate that mindfulness meditation can reduce long-term relapse (continuous cessation (\\> 30 days) of smoking cessation).\n\nThe participants will be randomized into two groups: the experimental group will perform six virtual reality sessions in a multisensory cabin at the rate of one session per week; the control group will be prescribed the gold standard treatment (nicotine patches and chewing gum).\n\nParticipants will be seen again at three and six months to assess whether or not there has been a smoking relapse.",[27],[655,656],"relapse","craving","2026-01-12",{"date":659,"type":37},"2026-01-13",{"date":661,"type":37},"2023-06-15",{"date":663,"type":21},"2026-12-15",{"name":665,"class":44},"Centre Hospitalier Henri Laborit",{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":670,"acronym":4,"eligibilityCriteria":671,"healthyVolunteers":16,"sex":17,"minAge":132,"maxAge":208,"enrollmentInfo":672,"targetDuration":4,"studyType":22,"phases":673,"briefSummary":675,"conditions":676,"keywords":677,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":178},"100473508","phase-1-oral-cannabidiol-for-tobacco-cessation-100473508","NCT05445804","Oral Cannabidiol for Tobacco Cessation","Inclusion Criteria:\n\n1. Have provided written informed consent\n2. Be between the ages of 18 and 65\n3. Report use of \\> 10 cigarettes per day for \\> 1 year with smoking status verified by either a positive breath carbon monoxide test (\\>8ppm) or urine cotinine test (\\>200ng\u002FmL) at screening\n4. Report interest in quitting tobacco in the next two months\n5. Are willing to engage in a series of practice quit attempts as part of the study.\n6. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests as determined by a licensed medical professional.\n7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study and for at least 30 days after the last study drug administration. Acceptable forms of contraception include: double barrier contraception or a combination of a barrier contraception and a hormonal implant, injectable, combined oral contraceptive, or a male partner who has had a vasectomy; intrauterine device or tubal ligation.\n\nExclusion Criteria:\n\n1. Meet Diagnostic and Statistical Manual-V criteria for substance use disorders except for nicotine or tobacco use disorders\n2. Are currently receiving or interested in immediately receiving behavioral treatment or medication for smoking cessation\n3. Test positive for drugs of abuse (except nicotine) and\u002For breath alcohol test at study admission\n4. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity.\n5. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n6. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding.\n7. Use of an over the counter, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the participant\n8. Use of a prescription medication (with the exception of birth control prescriptions) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the participant. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce\u002Finhibit CYP3A4 enzymes.\n9. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina).\n10. Have elevated serum liver transaminase (AST or ALT) above 2 x upper limit of normal, or elevated bilirubin above 1.5 x upper limit of normal.\n11. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.\n\n    \\-",{"count":607,"type":21},[674],"PHASE1","Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.",[296,489,104,27,511],[678,30,491,679],"Tobacco","CBD","2026-01-05",{"date":682,"type":37},"2026-01-07",{"date":684,"type":37},"2022-11-01",{"date":686,"type":21},"2027-02-01",{"name":43,"class":44}]